Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

• Status: Unknown status
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

• The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LiNanlin,Ph.D, Chief Physician,Clinical Professor
• Collaborator: Roche Pharma AG
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• HER2-negative breast cancer patients

• Without surgery

• Plans to neoadjuvant chemotherapy

Exclusion Criteria:

• HER2-positive breast cancer patients

• Post-operative patients